NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

Novartis looks odds on to extend the indications ... the phase 3 NATALEE trial reported at the ASCO congress. Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for ...

Two other CDK4/6 inhibitors – Novartis' Kisqali (ribociclib) and Eli Lilly's Verzenios (abemaciclib) – have already been approved by NICE for both first- and second-line use in advanced HR+ ...

and combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc‘s (NYSE: PFE) selective CDK4 inhibitor). The data showed that despite heavy pre-treatment, patients with PI3Kα ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

At Novartis, our continued success depends on our ability to proactively detect and manage risk. Therefore, risk management is an integral element of our Ethics, Risk and Compliance program. As part ...

After hours: 7 November at 6:28 pm GMT-5 ...

Novartis India Ltd., incorporated in the year 1947, is a Small Cap company (having a market cap of Rs 2,666.61 Crore) operating in Pharmaceuticals sector. Novartis India Ltd. key Products/Revenue ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...